Jada Bascom Foundation
All conditions

Inherited immune disorders

Leukocyte adhesion deficiency type I

Also called: LAD-I · LAD1 · ITGB2 deficiency · Integrin beta-2 deficiency · CD18 deficiency

What a donor has to do with this

An approved gene or cell therapy now exists for this condition and can be an alternative to a donor transplant. Which route fits a person depends on their situation, and that decision belongs to them and their treating team.

This is our reading of published transplant guidelines for this condition, not a measurement of how many people need a donor. Where a source actually counted donors, the figure and the people it counted are shown further down. Where none did, we say so rather than estimate.

What the evidence says

Who it affects
Typical onset/diagnosis: boys and girls are affected equally, and severe LAD-I causes serious infections from birth. Evidence: U.S. Immune Deficiency Foundation review (accessed 2026), describing cases worldwide; no markedly enriched geographic population was identified.
Treatments other than a transplant
Kresladi (marnetegragene autotemcel) — approved under accelerated approval — United States, 2026 — For pediatric severe LAD-I with biallelic ITGB2 variants and no available HLA-matched sibling donor.
If a transplant is used, the cells come from
bone marrow: used in opened IEI transplant guidance; disease-specific share was not reported; mobilized peripheral blood stem cells: used in opened IEI transplant guidance; disease-specific share was not reported; umbilical cord blood: used as an alternative in opened IEI transplant guidance; disease-specific share was not reported; dominance: no dominant graft source was reported in the opened disease-specific sources
How often the donor was unrelated
Not reported. No source we could read states this for this condition, so we do not give a number. An estimate here would be a guess dressed as evidence.

Where this gets complicated

The 2026 gene-therapy approval postdates transplant guidelines and applies only to severe pediatric LAD-I without a matched sibling donor.; LAD-I must not be merged with LAD-II or LAD-III, which have different genes, manifestations, and transplant evidence.

Written for transplant clinicians, not for patients. We quote it so you can see what the guidance actually says:
“who do not have an available human leukocyte antigen (HLA)-matched sibling donor for allogeneic hematopoietic stem cell transplantation (HSCT)”

It describes what teams consider in general. It cannot say what applies to any one person. Read the source.

We are not asking you to register on this page

An unrelated donor is not a usual part of treating this condition, so it would be dishonest to use this page to ask you to register. Other conditions in the library are a different story.

Related conditions

Others in inherited immune disorders. They are genuinely different diseases with different treatments — the group name is not a diagnosis.

Where this came from